TAAR1 and schizophrenia: This interest has largely focused on the most well-characterized family member, TAAR1, and its potential as a novel target for pharmacotherapy of psychiatric disorders, in particular schizophrenia (Revel et al., 2013) and drug abuse (Pei et al., 2016), and more recently metabolic disorders (Raab et al., 2016).